Figure 7. In vivo efficacy of translation initiation inhibitors for cancer therapy.

Mouse carrying xenografted human melanoma or breast cancer (~150 mm³) were randomly distributed to control and treatment groups and treated i.p. with the indicated daily doses of #1181 b.i.d. (A) or 4EGI-1 q.d. (B). Tumor dimensions were measured weekly and tumor volumes were calculated.